How many drugs treat Seasonal allergic rhinitis?

Drug Landscape tracks 10 marketed treatments for Seasonal allergic rhinitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/seasonal-allergic-rhinitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Seasonal allergic rhinitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Seasonal allergic rhinitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Seasonal allergic rhinitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Xyzal	LEVOCETIRIZINE	Sanofi	Histamine-1 Receptor Antagonist	Histamine H1 receptor	2007-01-01
Omnaris	CICLESONIDE	Covis	ciclesonide	Glucocorticoid receptor	2006-01-01
Omnaris	Alvesco	Takeda Gmbh	ciclesonide	Glucocorticoid receptor	2006-01-01
Clarinex	desloratadine	Generic (originally Schering-Plough/MSD)	Histamine-1 Receptor Antagonist [EPC]	5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1	2001-12-21
Propadrine	PHENYLPROPANOLAMINE	Alpharma Us Pharms	Indirectly Acting Sympathomimetic Amines	Sodium-dependent noradrenaline transporter	2000-01-01
Allegra	fexofenadine	Generic (originally Hoechst Marion Roussel/Sanofi)	Second-generation antihistamine	Solute carrier organic anion transporter family member 1A2, Multidrug resistance protein 1, Histamine H1 receptor	1996-07-25
Astelin	AZELASTINE	Bayer	Histamine-1 Receptor Antagonist	Histamine H1 receptor	1996-01-01
Zyrtec	cetirizine	Generic (originally UCB Pharma)	Second-generation antihistamine	Angiopoietin-1 receptor, Histamine H1 receptor, Potassium voltage-gated channel subfamily H member 2	1995-09-29
Semprex-D	ACRIVASTINE	Auxilium Pharms Inc	Histamine-1 Receptor Antagonist	Histamine H1 receptor	1994-01-01
Claritin	loratadine	Generic (originally Schering-Plough)	Second-generation antihistamine	Sodium-dependent neutral amino acid transporter B(0)AT2, Cytochrome P450 2C19, Multidrug resistance protein 1	1993-04-12

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 9 drugs in Seasonal allergic rhinitis
Bayer · 3 drugs in Seasonal allergic rhinitis
Generic (multiple manufacturers) · 2 drugs in Seasonal allergic rhinitis
Alpharma Us Pharms · 1 drug in Seasonal allergic rhinitis
Brooke Army Medical Center · 1 drug in Seasonal allergic rhinitis
Chattem · 1 drug in Seasonal allergic rhinitis
Generic (originally Hoechst Marion Roussel/Sanofi) · 1 drug in Seasonal allergic rhinitis
GSK · 1 drug in Seasonal allergic rhinitis
Covis · 1 drug in Seasonal allergic rhinitis
Auxilium Pharms Inc · 1 drug in Seasonal allergic rhinitis
Generic (originally Schering-Plough) · 1 drug in Seasonal allergic rhinitis
ANI Pharmaceuticals · 1 drug in Seasonal allergic rhinitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Seasonal allergic rhinitis:

Cite this brief

Drug Landscape (2026). Seasonal allergic rhinitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/seasonal-allergic-rhinitis. Accessed 2026-06-10.

Seasonal allergic rhinitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing